The company said revenue for the 3-month period ended June 30, 2025 was $1,348.0 million, compared with $1,223.2 million a year earlier, an increase of 10% (9% on a constant currency basis). It said income from operations rose 19%.

1. 01

   The company said revenue for the 3-month period ended June 30, 2025 was $1,348.0 million, compared with $1,223.2 million a year earlier, an increase of 10% (9% on a constant currency basis). It said income from operations rose 19%.

2. 02

   The company said gross margin for Q4 was 60.8%, an improvement of 230 basis points, and non-GAAP gross margin was 61.4%. It cited procurement, manufacturing and logistics efficiencies and favorable foreign currency movements as factors.

3. 03

   ResMed said operating cash flow for Q4 was $539 million, exceeding net income of $380 million. It said that during the quarter it paid dividends of $78 million and repurchased 419,000 shares for $100 million.

4. 04

   The company said its board of directors declared a quarterly cash dividend of $0.60 per share. The record date is August 14, 2025, and the payment date is September 18, 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.